# Niki BioSolutions Launches $1.396 Million At-The-Market Stock Offering Program

- URL: https://stocks.freetheai.org/news/niki-biosolutions-launches-1-396-million-at-the-market-stock-offering-program-5cb71c
- Published: 2026-10-09T21:13:00Z
- Category: company_news; sentiment: bearish; impact: low
- Symbols: [NASDAQ:NIKI](https://stocks.freetheai.org/symbols/NASDAQ-NIKI)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Niki BioSolutions, Inc. (NASDAQ:NIKI) has launched a new at-the-market equity program to sell up to $1.396 million of its common stock. The biotech firm entered into the agreement on October 9, 2026, to provide itself with flexible access to capital. Under the terms of the deal, shares will be sold from time to time at prevailing market prices.

H.C. Wainwright is serving as the primary sales agent for the offering and will receive a 3.0% placement fee on sales. Due to an undisclosed conflict of interest, Brookline Capital Markets is participating as a qualified independent underwriter. The program is highly flexible, allowing Niki BioSolutions or the agents to pause or end the arrangement at any time.

The move comes as the company seeks to raise equity capital. On the day of the announcement, shares of the company declined 7.41% to close at $4.00. Investors will likely watch how the company utilizes any proceeds raised from the program and the potential dilutive impact of the new share sales on existing stockholders.

## Key points

- Niki BioSolutions established an at-the-market equity program to sell up to $1.396 million in common stock.
- Share sales will take place at prevailing market prices through sales agent H.C. Wainwright.
- H.C. Wainwright will receive a 3.0% placement fee for shares sold under the agreement.
- Brookline Capital Markets will act as a qualified independent underwriter due to a conflict.
- The offering program is effective as of October 9, 2026, and can be terminated at will.

## Questions and answers

### What is the size of Niki BioSolutions' new stock offering?

Niki BioSolutions has launched an at-the-market equity program to sell up to $1.396 million of its common stock.

### Who is managing the Niki BioSolutions ATM program?

H.C. Wainwright is the primary sales agent, receiving a 3.0% placement fee. Brookline Capital Markets is serving as a qualified independent underwriter due to a conflict of interest.

### When does the Niki BioSolutions stock offering end?

The agreement became effective on October 9, 2026, and can be suspended or terminated at any time by the company or the agents.